Prognosis of breast cancer patients treated with sentinel node biopsy in Japan

Shigeru Imoto, Noriaki Wada, Kohji Murakami, Takahiro Hasebe, Atsushi Ochiai, Satoshi Ebihara

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Sentinel node biopsy predicts accurate pathological nodal staging. The survival of node-negative breast cancer patients should be evaluated between the patients treated with sentinel node biopsy alone and those treated with axillary lymph node dissection. Methods: Ninety- seven patients with negative axillary nodes underwent sentinel node biopsy immediately followed by axillary lymph node dissection between January 1998 and June 1999 (the ALND group). Since then, if sentinel lymph nodes were negative on the frozen-section diagnosis, 112 patients underwent sentinel node biopsy alone without axillary lymph node dissection between July 1999 and December 2000 (the SNB group). We retrospectively observed the outcome of the two study groups. Results: Median follow-up was 52 months in all patients. Relaps e-free survival rates at 3 years in the ALND and SNB groups were 94% and 93%, respectively. Five of the 112 patients in the SNB group had overt axillary metastases. Three of them with axillary metastases alone were treated with delayed axillary lymph node dissection. These three patients have been free of other events for 3 years after local salvage treatment. Conclusions: Sentinel node biopsy will emerge as a standard method to diagnose axillary nodal staging for clinically node-negative breast cancer patients.

Original languageEnglish
Pages (from-to)452-456
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume34
Issue number8
DOIs
Publication statusPublished - 2004 Aug
Externally publishedYes

Fingerprint

Japan
Breast Neoplasms
Biopsy
Lymph Node Excision
Neoplasm Metastasis
Salvage Therapy
cyhalothrin
Frozen Sections
Survival Rate
Outcome Assessment (Health Care)
Survival

Keywords

  • Axillary lymph node dissection
  • Breast cancer
  • Prognosis
  • Sentinel node biopsy

ASJC Scopus subject areas

  • Oncology

Cite this

Imoto, S., Wada, N., Murakami, K., Hasebe, T., Ochiai, A., & Ebihara, S. (2004). Prognosis of breast cancer patients treated with sentinel node biopsy in Japan. Japanese Journal of Clinical Oncology, 34(8), 452-456. https://doi.org/10.1093/jjco/hyh077

Prognosis of breast cancer patients treated with sentinel node biopsy in Japan. / Imoto, Shigeru; Wada, Noriaki; Murakami, Kohji; Hasebe, Takahiro; Ochiai, Atsushi; Ebihara, Satoshi.

In: Japanese Journal of Clinical Oncology, Vol. 34, No. 8, 08.2004, p. 452-456.

Research output: Contribution to journalArticle

Imoto, S, Wada, N, Murakami, K, Hasebe, T, Ochiai, A & Ebihara, S 2004, 'Prognosis of breast cancer patients treated with sentinel node biopsy in Japan', Japanese Journal of Clinical Oncology, vol. 34, no. 8, pp. 452-456. https://doi.org/10.1093/jjco/hyh077
Imoto, Shigeru ; Wada, Noriaki ; Murakami, Kohji ; Hasebe, Takahiro ; Ochiai, Atsushi ; Ebihara, Satoshi. / Prognosis of breast cancer patients treated with sentinel node biopsy in Japan. In: Japanese Journal of Clinical Oncology. 2004 ; Vol. 34, No. 8. pp. 452-456.
@article{a01df5bc47704e81aba4f2189d86aeac,
title = "Prognosis of breast cancer patients treated with sentinel node biopsy in Japan",
abstract = "Background: Sentinel node biopsy predicts accurate pathological nodal staging. The survival of node-negative breast cancer patients should be evaluated between the patients treated with sentinel node biopsy alone and those treated with axillary lymph node dissection. Methods: Ninety- seven patients with negative axillary nodes underwent sentinel node biopsy immediately followed by axillary lymph node dissection between January 1998 and June 1999 (the ALND group). Since then, if sentinel lymph nodes were negative on the frozen-section diagnosis, 112 patients underwent sentinel node biopsy alone without axillary lymph node dissection between July 1999 and December 2000 (the SNB group). We retrospectively observed the outcome of the two study groups. Results: Median follow-up was 52 months in all patients. Relaps e-free survival rates at 3 years in the ALND and SNB groups were 94{\%} and 93{\%}, respectively. Five of the 112 patients in the SNB group had overt axillary metastases. Three of them with axillary metastases alone were treated with delayed axillary lymph node dissection. These three patients have been free of other events for 3 years after local salvage treatment. Conclusions: Sentinel node biopsy will emerge as a standard method to diagnose axillary nodal staging for clinically node-negative breast cancer patients.",
keywords = "Axillary lymph node dissection, Breast cancer, Prognosis, Sentinel node biopsy",
author = "Shigeru Imoto and Noriaki Wada and Kohji Murakami and Takahiro Hasebe and Atsushi Ochiai and Satoshi Ebihara",
year = "2004",
month = "8",
doi = "10.1093/jjco/hyh077",
language = "English",
volume = "34",
pages = "452--456",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Prognosis of breast cancer patients treated with sentinel node biopsy in Japan

AU - Imoto, Shigeru

AU - Wada, Noriaki

AU - Murakami, Kohji

AU - Hasebe, Takahiro

AU - Ochiai, Atsushi

AU - Ebihara, Satoshi

PY - 2004/8

Y1 - 2004/8

N2 - Background: Sentinel node biopsy predicts accurate pathological nodal staging. The survival of node-negative breast cancer patients should be evaluated between the patients treated with sentinel node biopsy alone and those treated with axillary lymph node dissection. Methods: Ninety- seven patients with negative axillary nodes underwent sentinel node biopsy immediately followed by axillary lymph node dissection between January 1998 and June 1999 (the ALND group). Since then, if sentinel lymph nodes were negative on the frozen-section diagnosis, 112 patients underwent sentinel node biopsy alone without axillary lymph node dissection between July 1999 and December 2000 (the SNB group). We retrospectively observed the outcome of the two study groups. Results: Median follow-up was 52 months in all patients. Relaps e-free survival rates at 3 years in the ALND and SNB groups were 94% and 93%, respectively. Five of the 112 patients in the SNB group had overt axillary metastases. Three of them with axillary metastases alone were treated with delayed axillary lymph node dissection. These three patients have been free of other events for 3 years after local salvage treatment. Conclusions: Sentinel node biopsy will emerge as a standard method to diagnose axillary nodal staging for clinically node-negative breast cancer patients.

AB - Background: Sentinel node biopsy predicts accurate pathological nodal staging. The survival of node-negative breast cancer patients should be evaluated between the patients treated with sentinel node biopsy alone and those treated with axillary lymph node dissection. Methods: Ninety- seven patients with negative axillary nodes underwent sentinel node biopsy immediately followed by axillary lymph node dissection between January 1998 and June 1999 (the ALND group). Since then, if sentinel lymph nodes were negative on the frozen-section diagnosis, 112 patients underwent sentinel node biopsy alone without axillary lymph node dissection between July 1999 and December 2000 (the SNB group). We retrospectively observed the outcome of the two study groups. Results: Median follow-up was 52 months in all patients. Relaps e-free survival rates at 3 years in the ALND and SNB groups were 94% and 93%, respectively. Five of the 112 patients in the SNB group had overt axillary metastases. Three of them with axillary metastases alone were treated with delayed axillary lymph node dissection. These three patients have been free of other events for 3 years after local salvage treatment. Conclusions: Sentinel node biopsy will emerge as a standard method to diagnose axillary nodal staging for clinically node-negative breast cancer patients.

KW - Axillary lymph node dissection

KW - Breast cancer

KW - Prognosis

KW - Sentinel node biopsy

UR - http://www.scopus.com/inward/record.url?scp=7944231201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944231201&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyh077

DO - 10.1093/jjco/hyh077

M3 - Article

VL - 34

SP - 452

EP - 456

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 8

ER -